TriSalus Life Sciences Inc. (TLSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has a cash flow conversion efficiency ratio of -2.536x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.61 Million) by net assets ($6.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TriSalus Life Sciences Inc. market capitalisation for the company's overall valuation and market capitalisation.
TriSalus Life Sciences Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how TriSalus Life Sciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
TriSalus Life Sciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their cash flow conversion efficiency. Explore TriSalus Life Sciences Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
0.023x |
|
Interarch Building Products Limited
NSE:INTERARCH
|
0.048x |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
-0.297x |
|
Asia Aviation Public Company Limited
F:55AA
|
0.044x |
|
Best Pacific International Holdings Limited
F:NWQ
|
0.050x |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
-0.008x |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
N/A |
|
AVCON Information Tech
SHE:300074
|
0.014x |
Annual Cash Flow Conversion Efficiency for TriSalus Life Sciences Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of TriSalus Life Sciences Inc. from 2021 to 2025. View latest TriSalus Life Sciences Inc. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.86 Million | $-18.01 Million | 0.532x | -66.28% |
| 2024-12-31 | $-25.89 Million | $-40.84 Million | 1.577x | -15.60% |
| 2023-12-31 | $-27.07 Million | $-50.58 Million | 1.869x | -28.73% |
| 2022-12-31 | $-12.32 Million | $-32.31 Million | 2.622x | +456.99% |
| 2021-12-31 | $30.90 Million | $-22.70 Million | -0.734x | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more